Elafibranor
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Elafibranor |
| DrugBank ID | DB05187 |
| Brand Names (EU) | Iqirvo |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.86% |
Approved Indication (EMA)
Iqirvo is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | amenorrhea (disease) | 99.86% | DL |
| 2 | non-syndromic esophageal malformation | 98.92% | DL |
| 3 | bone Paget disease | 98.86% | DL |
| 4 | dentinogenesis imperfecta | 98.52% | DL |
| 5 | squamous cell carcinoma | 98.47% | DL |
| 6 | rectal cloacogenic carcinoma | 98.46% | DL |
| 7 | gallbladder adenosquamous carcinoma | 98.45% | DL |
| 8 | deafness, autosomal dominant 39, with dentinogenesis imperfecta 1 | 98.44% | DL |
| 9 | adenosquamous breast carcinoma | 98.44% | DL |
| 10 | acantholytic variant squamous cell breast carcinoma | 98.44% | DL |
| 11 | large cell keratinizing variant squamous cell breast carcinoma | 98.43% | DL |
| 12 | spindle cell variant squamous cell breast carcinoma | 98.43% | DL |
| 13 | adenosquamous prostate carcinoma | 98.43% | DL |
| 14 | urethral verrucous carcinoma | 98.43% | DL |
| 15 | carcinoma of lip | 98.43% | DL |
| 16 | metaplastic breast carcinoma | 98.43% | DL |
| 17 | sarcomatoid squamous cell skin carcinoma | 98.43% | DL |
| 18 | dentin dysplasia | 98.43% | DL |
| 19 | ethmoid sinus squamous cell carcinoma | 98.43% | DL |
| 20 | vulvar keratinizing squamous cell carcinoma | 98.42% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.